My bookmarksSign up free

97/348/EC: Commission Decision of 23 May 1997 for the purchase by the Community of foot-and-mouth disease antigens and for the formulation, production, bottling and distribution of vaccines against foot-and-mouth disease (Text with EEA relevance)

97/348/EC: Commission Decision of 23 May 1997 for the purchase by the Community of foot-and-mouth disease antigens and for the formulation, production, bottling and distribution of vaccines against foot-and-mouth disease (Text with EEA relevance)

Decision · 6 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

1. The Community shall purchase the following strains of foot-and-mouth disease antigen: - A22 Iraq: 2 000 000 doses - C1: 5 000 000 doses - ASIA 1: 5 000 000 doses up to a maximum cost of ECU 2,4 million. 2. The antigen mentioned in paragraph 1 shall be supplied by Rhône Mérieux. 3. The Community shall make arrangements for formulation, production, bottling and distribution of vaccines against foot-and-mouth disease produced from antigens mentioned in paragraph 2 initially up to a maximum cost of ECU 1,5 million. 4. The action referred to in paragraph 3 shall be organized by the Commission.

Article 2

1. The Community shall make arrangements for formulation, production, bottling and distribution of vaccines against foot-and-mouth disease produced from antigens kept in existing antigen banks, initially up to a maximum cost of ECU 1,5 million. 2. The action referred to in paragraph 1 shall be organized by the Commission.

Article 3

The measures mentioned in Article 1 (3) and Article 2 (1) shall be carried out by the Commission in cooperation with Rhône Mérieux.

Article 4

1. To meet the objectives of Articles 1, 2 and 3 the Commission shall conclude contracts, in the name of the European Community, with Rhône Mérieux. 2. The Director-General of the Directorate-General for Agriculture shall be authorized to sign the contracts on behalf of the European Commission. 3. Payment to Rhône Mérieux shall be made in accordance with the terms of the contracts provided for in paragraph 1.

Article 5

The antigen referred to in Article 1 (1) shall be divided between the existing antigen banks as follows: (a) Lyon: 2 000 000 doses of A22 Iraq, (b) Brescia: 2,5 million doses of C1 and of ASIA 1, (c) Pirbright: 2,5 million doses of C1 and of ASIA 1.

Article 6

This Decision is addressed to the Member States. Done at Brussels, 23 May 1997. For the Commission Franz FISCHLER Member of the Commission (1) OJ No L 224, 18. 8. 1990, p. 19. (2) OJ No L 168, 2. 7. 1994, p. 31. (3) OJ No L 368, 31. 12. 1991, p. 21. (4) OJ No L 280, 13. 11. 1993, p. 33. (5) OJ No L 269, 11. 11. 1995, p. 29. (6) OJ No C 346, 16. 11. 1996, p. 27.

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

What to look at next